Tobramycin and Dexamethasone
Medically reviewed by Drugs.com. Last updated on Sep 4, 2020.
(toe bra MYE sin & deks a METH a sone)
- Dexamethasone and Tobramycin
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
TobraDex: Tobramycin 0.3% and dexamethasone 0.1% (3.5 g) [contains chlorobutanol]
Suspension, ophthalmic: Tobramycin 0.3% and dexamethasone 0.1% (2.5 mL, 5 mL, 10 mL)
TobraDex: Tobramycin 0.3% and dexamethasone 0.1% (2.5 mL, 5 mL, 10 mL) [contains benzalkonium chloride]
TobraDex ST: Tobramycin 0.3% and dexamethasone 0.05% (5 mL) [contains benzalkonium chloride]
Brand Names: U.S.
- TobraDex ST
- Antibiotic/Corticosteroid, Ophthalmic
Tobramycin: Interferes with bacterial protein synthesis by binding to 30S ribosomal subunit resulting in a defective bacterial cell membrane.
Dexamethasone: Decreases inflammation by suppression of neutrophil migration, decreased production of inflammatory mediators, and reversal of increased capillary permeability; suppresses normal immune response.
Use: Labeled Indications
Ocular inflammatory conditions: Treatment of steroid-responsive ocular inflammatory conditions (where either a superficial bacterial ocular infection or the risk of a bacterial ocular infection exists) of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe; chronic anterior uveitis; corneal injury from chemical, radiation or thermal burns; penetration of foreign bodies.
Hypersensitivity to tobramycin, dexamethasone, or any component of the formulation; viral diseases of the cornea and conjunctiva (including epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella); mycobacterial infection of the eye; fungal diseases of ocular structure.
Canadian labeling: Additional contraindications (not in US labeling): Patients with known or suspected hypersensitivity to other aminoglycosides; after uncomplicated removal of a corneal foreign body; untreated parasitic or untreated acute purulent infections of the eye.
Documentation of allergenic cross-reactivity for corticosteroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
Ocular inflammatory conditions: Ophthalmic:
Ointment: Apply ~1/2-inch ribbon in the conjunctival sac of the affected eye(s) up to 3 to 4 times daily
TobraDex: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; may be increased to 1 to 2 drops every 2 hours for the first 24 to 48 hours, then reduce to less frequent intervals as signs and symptoms improve
TobraDex ST: Instill 1 drop into the conjunctival sac of the affected eye(s) every 4 to 6 hours; may be increased to 1 drop every 2 hours for the first 24 to 48 hours, then reduce to less frequent intervals as signs and symptoms improve
Refer to adult dosing.
Ocular inflammatory conditions: Children ≥2 years and Adolescents: Refer to adult dosing.
Contact lenses should not be worn during therapy. For topical ophthalmic use only; to avoid contamination, do not touch container tip to eyelids or other surfaces when placing drops or ointment in eyes.
Ointment: Apply ointment into pocket between eyeball and lower lid; patient should look downward before closing eye.
Suspension: Shake well before using. Tilt head back, instill suspension in conjunctival sac and close eye(s). Apply light finger pressure on lacrimal sac for 1 minute following instillation.
Ointment: Store at 2°C to 25°C (36°F to 77°F).
Suspension: Store at 8°C to 25°C (46°F to 77°F).
TobraDex ST: Store at 2°C to 25°C (36°F to 77°F). Protect from light.
CYP3A4 Inhibitors (Strong): May increase the serum concentration of DexAMETHasone (Ophthalmic). Monitor therapy
Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed. Monitor therapy
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Also see individual agents.
1% to 10%:
Cardiovascular: Increased blood pressure (≤1%)
Hypersensitivity: Hypersensitivity reaction (<4%)
Nervous system: Headache (≤1%)
Ophthalmic: Blepharitis (<4%), conjunctival erythema (<4%), eyelid pruritus (<4%)
Dermatologic: Erythema multiforme
Concerns related to adverse effects:
• Hypersensitivity reactions: Sensitivity varying from local to generalized effects (eg, erythema, pruritus, urticaria, skin rash, anaphylaxis, anaphylactoid reaction, bullous reaction) to topically applied aminoglycosides may occur; discontinue if sensitivity reaction occurs. Cross-sensitivity to other aminoglycoside antibiotics may occur.
• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary ocular infections (including fungal infections). Acute purulent or parasitic ocular infections may be masked or exacerbated with use. Fungal infection should be suspected in any patient with persistent corneal ulceration who has received corticosteroids.
• Ocular effects: Prolonged use may result in glaucoma, injury to the optic nerve, visual defects in acuity and field of vision, and formation of posterior subcapsular cataracts. Use with caution in presence of glaucoma (steroids increase intraocular pressure). Perforation may occur with topical steroids in diseases which thin the cornea or sclera. Steroid use after cataract surgery may delay healing and increase the incidence of bleb formation. Intraocular pressure should be monitored if this product is used >10 days.
• Ocular herpes simplex: Use with extreme caution in patients with a history of ocular herpes simplex; use of corticosteroids may prolong the course and exacerbate severity of infection.
• Contact lens wearers: May contain benzalkonium chloride (ophthalmic suspension) which may be adsorbed by contact lenses; contact lenses should not be worn during treatment of ophthalmic infections.
• Appropriate use: For topical ophthalmic use only. A maximum of 8 g of ointment or 20 mL of suspension should be prescribed initially; patients should be evaluated prior to additional refills. Patients should be re-evaluated if symptoms do not improve after 2 days. Monitor intraocular pressure if this product is used >10 days. Initial prescription and renewal of medication should be made by health care provider only after examination with the aid of magnification such as slit lamp biomicroscopy or fluorescein staining (if appropriate). Inadvertent contamination of multiple-dose ophthalmic bottle dropper and tips has caused bacterial keratitis.
Monitor intraocular pressure with use >10 days and in patients with glaucoma; signs/symptoms of secondary infection; re-evaluate if signs and symptoms persist beyond 2 days.
Adverse events have been observed with topical corticosteroids in animal reproduction studies. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease potential exposure to the fetus (Samples 1988). See individual agents.
What is this drug used for?
• It is used to treat or prevent eye infections.
• It is used to treat eye swelling.
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
• Vision changes
• Eye pain
• Severe eye irritation
• Eyelid swelling
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.
More about dexamethasone / tobramycin ophthalmic
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- 17 Reviews
- Drug class: ophthalmic steroids with anti-infectives
- Drug Information
- Tobramycin and dexamethasone Ophthalmic (Advanced Reading)
- Tobramycin and Dexamethasone Eye Drops
- Tobramycin and Dexamethasone Eye Ointment
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.